Azacitidine vs Azacitidine (Onureg)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: DNMT1 (DNA methyltransferase 1) · full Acute Myeloid Leukemia pipeline

Azacitidine

Marketed by Bristol-Myers Squibb

Phase 3 in Acute Myeloid Leukemiasmall molecule
Partial signal

NCT00887068 · Phase 3 · completed

This randomized Phase 3 trial assigned 187 patients with AML or MDS in remission after allogeneic stem cell transplant to azacitidine maintenance (93) or no intervention (94). The primary endpoint was relapse-free survival. Median relapse-free survival was 2.07 vs 1.28 years, but the difference was not significant (P=.43), so the primary was missed. Source: the peer-reviewed paper (Oran et al., Blood Adv 2020).

Next expected readout: November 2026 · NCT03850574 (registry estimate)

Reported efficacy

Relapse-free Survival (RFS) (3 years): Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). (missed)

Result source: NCT00887068

Azacitidine (Onureg)

Marketed by Bristol-Myers Squibb

Approved in Acute Myeloid Leukemiasmall molecule
Weak signal

NCT04102020 · Phase 3 · completed

The study was nonrandomized, open-label, sequential, and had no comparator arm; its primary endpoint was dose-limiting toxicity during cycle 1, a safety measure assessed descriptively across dose groups. These design features do not allow a controlled comparison of treatment benefit, so the evidence is limited despite enrollment of 112 participants.

Next expected readout: March 2027 · NCT05287568 (registry estimate)

Reported efficacy

Kaplan-Meier (K-M) Estimate for Overall Survival (OS) (Day 1 (randomization) up to data cut off date of 15 July 2019; median follow-up for OS estimated by the reverse K-M method was 41.2 months for all participants.): QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). (met)

Result source: NCT01757535

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAzacitidineAzacitidine (Onureg)
OS, median10.4bn 241NCT01074047
20 other results
24.7 vs 14.8+9.9 vs placebon 238NCT01757535
Complete remission13.3%b400 mg + 75 mg · n 30NCT03941964
1 other result
  • 26.7% 400 mg + 20 mg · n 30 · Phase 3 · secondary NCT03941964
—Not posted · NCT04173533
Event-free survival, median17.7 vs 15.7vs Azacitidine20 mg/m^2 + 75 mg/m^2 · n 227NCT03268954
17 other results
—Not posted · NCT04173533
Duration of response, median17.1 vs 18.3vs Azacitidine20 mg/m^2 + 75 mg/m^2 · n 64NCT03268954
15 other results
—Not posted · NCT04173533

OS, median

Azacitidine
10.4bn 241NCT01074047
20 other results
Azacitidine (Onureg)
24.7 vs 14.8+9.9 vs placebon 238NCT01757535

Complete remission

Azacitidine
13.3%b400 mg + 75 mg · n 30NCT03941964
1 other result
  • 26.7% 400 mg + 20 mg · n 30 · Phase 3 · secondary NCT03941964
Azacitidine (Onureg)
—Not posted · NCT04173533

Event-free survival, median

Azacitidine
17.7 vs 15.7vs Azacitidine20 mg/m^2 + 75 mg/m^2 · n 227NCT03268954
17 other results
Azacitidine (Onureg)
—Not posted · NCT04173533

Duration of response, median

Azacitidine
17.1 vs 18.3vs Azacitidine20 mg/m^2 + 75 mg/m^2 · n 64NCT03268954
15 other results
Azacitidine (Onureg)
—Not posted · NCT04173533
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Azacitidine: 7 of 7 rows · Azacitidine (Onureg): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAzacitidine
Rows use multiple source trials
Azacitidine (Onureg)
Rows use multiple source trials
Overall Survival
time to event · months
No placebo or comparator arm
10.4 monthsa,b,c,d
NCT01074047 · Phase 3 · registry result, not featured evidence
16 other source trials
6.2 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence
5.2 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
7.4 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
11.7 months
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
8.4 months
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
5.9 months
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
19.08 months
NCT01912274 · Phase 2 · registry result, not featured evidence · combination
20.4 months
NCT00387647 · Phase 2 · registry result, not featured evidence
11.6 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence
NA months
NCT02719574 · Phase 1/2 · registry result, not featured evidence
1.2 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence
25.2 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
11.6 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
10.2 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
14 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence
18.7 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
NA months300 mg Days 1-7e,a,b,c,d
NCT01835587 · Phase 1/2 · registry result, not featured evidence
show 3 more doses
NA months200 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence
NA months200 mg Days 1-7
NCT01835587 · Phase 1/2 · registry result, not featured evidence
NA months150 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Relapse-free Survival
time to event · months
25.2 vs 15.6 Standard of Care months*f,g,d
NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to months from 2.1 years as posted
10.2 vs 4.8 placebo monthsf,g,d
NCT01757535 · Phase 3 · combination
Relapse-free Survival
time to event · months
No placebo or comparator arm
9.3 monthsa,b,c,d
NCT01074047 · Phase 3 · registry result, not featured evidence
5 other source trials
3.5 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence
9.4 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
13.3 months
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
12.5 months @ 52wk
NCT03931291 · Phase 2 · registry result, not featured evidence · combination
18.4 months
NCT02719574 · Phase 1/2 · registry result, not featured evidence
8.38 months*300 mg Days 1-7e,a,b,c,d
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 255 days as posted
show 3 more doses
NA months200 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence
30.26 months*200 mg Days 1-7
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 921 days as posted
NA months150 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Dropout rate
6.5%h
NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 40 more results
12.3%20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
66.7%
NCT04842604 · Phase 3 · registry result, not featured evidence · combination
76.7%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
63.3%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
—Azacitidine
NCT01074047 · Phase 3 · registry result, not featured evidence
90%Azacitidine (AZA)
NCT01074047 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneAzacitidine
NCT03092674 · Phase 2/3 · registry result, not featured evidence
n/a: no completion milestoneAzacitidine + Nivolumab
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
—Azacitidine +Midostaurin
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
n/a: no completion milestone20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01995578 · Phase 2 · registry result, not featured evidence
88.2%Newly Diagnosed Non-APL AML: Tamib
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
92.9%R/R Non-APL AML: Tamibarotene and
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03931291 · Phase 2 · registry result, not featured evidence · combination
7.4%
NCT01168219 · Phase 2 · registry result, not featured evidence
0%
NCT02196857 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneAzacitidine Plus Lenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence
3.2%Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
—Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01912274 · Phase 2 · registry result, not featured evidence · combination
75%
NCT00387647 · Phase 2 · registry result, not featured evidence
0%
NCT01083706 · Phase 2 · registry result, not featured evidence
—Arm A (Azacitidine)
NCT00313586 · Phase 2 · registry result, not featured evidence
—Arm B (Azacitidine + Entinostat)
NCT00313586 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00382590 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00326170 · Phase 2 · registry result, not featured evidence · combination
—Phase 1: FT-2102 (Single Agent)
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone190 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg + 20 mg/m^2i
NCT04102020 · Phase 3 · combination
show 9 more results
n/a: no completion milestone400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · combination
n/a: no completion milestone400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · combination
n/a: no completion milestone400 mg + 200 mg
NCT04102020 · Phase 3 · combination
n/a: no completion milestone400 mg + 300 mg
NCT04102020 · Phase 3 · combination
n/a: no completion milestone
NCT01757535 · Phase 3 · combination
100%300 mg Days 1-7 (Cohort 2)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
47.4%200 mg Days 1-14 (Cohort 3)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
66.7%200 mg Days 1-7 (Cohort 1)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
50%150 mg Days 1-14 (Cohort 3A)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—h
NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 40 more results
—20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
—
NCT04842604 · Phase 3 · registry result, not featured evidence · combination
3.3%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
26.7%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
—Azacitidine
NCT01074047 · Phase 3 · registry result, not featured evidence
36.9%Azacitidine (AZA)
NCT01074047 · Phase 3 · registry result, not featured evidence
23.1%Azacitidine
NCT03092674 · Phase 2/3 · registry result, not featured evidence
20%Azacitidine + Nivolumab
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
—Azacitidine +Midostaurin
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
22.9%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
—
NCT01995578 · Phase 2 · registry result, not featured evidence
0%Newly Diagnosed Non-APL AML: Tamib
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
0%R/R Non-APL AML: Tamibarotene and
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
—
NCT03931291 · Phase 2 · registry result, not featured evidence · combination
—
NCT01168219 · Phase 2 · registry result, not featured evidence
—
NCT02196857 · Phase 2 · registry result, not featured evidence · combination
17.9%Azacitidine Plus Lenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence · combination
26.7%Lenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence
—Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
—Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
—
NCT01912274 · Phase 2 · registry result, not featured evidence · combination
—
NCT00387647 · Phase 2 · registry result, not featured evidence
—
NCT01083706 · Phase 2 · registry result, not featured evidence
—Arm A (Azacitidine)
NCT00313586 · Phase 2 · registry result, not featured evidence
—Arm B (Azacitidine + Entinostat)
NCT00313586 · Phase 2 · registry result, not featured evidence · combination
—
NCT00382590 · Phase 2 · registry result, not featured evidence · combination
—
NCT00326170 · Phase 2 · registry result, not featured evidence · combination
—Phase 1: FT-2102 (Single Agent)
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
40%190 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
14.3%100 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
4.3%400 mg + 20 mg/m^2i
NCT04102020 · Phase 3 · combination
show 9 more results
0%400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · combination
0%400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · combination
3.3%400 mg + 200 mg
NCT04102020 · Phase 3 · combination
0%400 mg + 300 mg
NCT04102020 · Phase 3 · combination
13%
NCT01757535 · Phase 3 · combination
0%300 mg Days 1-7 (Cohort 2)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
10.5%200 mg Days 1-14 (Cohort 3)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
0%200 mg Days 1-7 (Cohort 1)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
50%150 mg Days 1-14 (Cohort 3A)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Serious AEs
0%h
NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 40 more results
70%20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
22.2%
NCT04842604 · Phase 3 · registry result, not featured evidence · combination
63.3%400 mg + 75 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
73.3%400 mg + 20 mg
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
79.7%Azacitidine
NCT01074047 · Phase 3 · registry result, not featured evidence
—Azacitidine (AZA)
NCT01074047 · Phase 3 · registry result, not featured evidence
36%Azacitidine
NCT03092674 · Phase 2/3 · registry result, not featured evidence
80%Azacitidine + Nivolumab
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
73.9%Azacitidine +Midostaurin
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
76.5%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
31.3%
NCT01995578 · Phase 2 · registry result, not featured evidence
84.3%Newly Diagnosed Non-APL AML: Tamib
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
71.4%R/R Non-APL AML: Tamibarotene and
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
39.4%
NCT03931291 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT01168219 · Phase 2 · registry result, not featured evidence
87.5%
NCT02196857 · Phase 2 · registry result, not featured evidence · combination
76.3%Azacitidine Plus Lenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence · combination
92.9%Lenalidomide
NCT01358734 · Phase 2 · registry result, not featured evidence
50%Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
69.2%Vorinostat With Azacitidine, Phase
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
100%
NCT01912274 · Phase 2 · registry result, not featured evidence · combination
8.3%
NCT00387647 · Phase 2 · registry result, not featured evidence
7.7%
NCT01083706 · Phase 2 · registry result, not featured evidence
92.9%Arm A (Azacitidine)
NCT00313586 · Phase 2 · registry result, not featured evidence
94.9%Arm B (Azacitidine + Entinostat)
NCT00313586 · Phase 2 · registry result, not featured evidence · combination
100%
NCT00382590 · Phase 2 · registry result, not featured evidence · combination
91.2%
NCT00326170 · Phase 2 · registry result, not featured evidence · combination
62.5%Phase 1: FT-2102 (Single Agent)
NCT02719574 · Phase 1/2 · registry result, not featured evidence
76.9%Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
75.2%Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
33.3%Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
80%Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
60%Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
85.7%Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
65%Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
80%Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2 · registry result, not featured evidence
81.8%Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
80%190 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
100%100 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
100%50 mg
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
21.7%400 mg + 20 mg/m^2i
NCT04102020 · Phase 3 · combination
show 9 more results
30.4%400 mg + 36 mg/m^2
NCT04102020 · Phase 3 · combination
25%400 mg + 50 mg/m^2
NCT04102020 · Phase 3 · combination
16.7%400 mg + 200 mg
NCT04102020 · Phase 3 · combination
18.8%400 mg + 300 mg
NCT04102020 · Phase 3 · combination
46.6%
NCT01757535 · Phase 3 · combination
75%300 mg Days 1-7 (Cohort 2)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
31.6%200 mg Days 1-14 (Cohort 3)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
33.3%200 mg Days 1-7 (Cohort 1)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
50%150 mg Days 1-14 (Cohort 3A)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
h
poor graft function 33.3%
thrombocytopenia 33.3%
hepatic 9.2%
NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 39 more results
20 mg/m^2 + 75 mg/m^2
constipation 36.8%
anaemia 35%
nausea 35%
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
neutropenia 44.4% (placebo 40%)
anaemia 11.1% (placebo 0%)
c-reactive protein increased 11.1% (placebo 0%)
NCT04842604 · Phase 3 · registry result, not featured evidence · combination
400 mg + 75 mg
anaemia 76.7%
neutrophil count decreased 63.3%
nausea 56.7%
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
400 mg + 20 mg
anaemia 80%
platelet count decreased 53.3%
white blood cell count decreased 53.3%
NCT03941964 · Phase 3 · registry result, not featured evidence · combination
constipation 41.9%
nausea 39.4%
diarrhoea 36.9%
NCT01074047 · Phase 3 · registry result, not featured evidence
white blood cell decreased 72%
hyponatremia 56%
anemia 52%
NCT03092674 · Phase 2/3 · registry result, not featured evidence
white blood cell decreased 52%
anemia 48%
anorexia 48%
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
constipation 73.9%
fatigue 65.2%
white blood cell decreased 65.2%
NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination
20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
neutropenia 58%
thrombocytopenia 45.7%
constipation 42%
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
nausea 37.5%
vomiting 28.1%
alanine aminotransferase increased 15.6%
NCT01995578 · Phase 2 · registry result, not featured evidence
constipation 47.1%
decreased appetite 47.1%
nausea 47.1%
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
nausea 50%
diarrhoea 39.3%
constipation 35.7%
NCT02807558 · Phase 2 · registry result, not featured evidence · combination
nausea 60.6%
platelet count decreased 48.5%
vomitting 45.5%
NCT03931291 · Phase 2 · registry result, not featured evidence · combination
anemia 87.9%
neutrophil count decreased 84.8%
platelet count decreased 84.8%
NCT01168219 · Phase 2 · registry result, not featured evidence
diarrhea 25%
fatigue 25%
febrile neutropenia 25%
NCT02196857 · Phase 2 · registry result, not featured evidence · combination
constipation 63.2%
diarrhoea 50%
nausea 50%
NCT01358734 · Phase 2 · registry result, not featured evidence · combination
fatigue 57.1%
constipation 50%
hypokalaemia 50%
NCT01358734 · Phase 2 · registry result, not featured evidence
constipation 23.3%
nausea 20%
infection 16.7%
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.4%
nausea 38.5%
constipation 32.7%
NCT00948064 · Phase 2 · registry result, not featured evidence · combination
nausea 48%
fatigue 40%
thrombocytopenia 38%
NCT01912274 · Phase 2 · registry result, not featured evidence · combination
platelets - low 79.2%
neutrophils/granulocytes (anc/agc) - low 75%
leukocytes (total wbc) - low 62.5%
NCT00387647 · Phase 2 · registry result, not featured evidence
thrombocytopenia 12.8%
hypoxia 7.7%
anemia 5.1%
NCT01083706 · Phase 2 · registry result, not featured evidence
hemoglobin 80.8%
fatigue 71.7%
leukocytes 67.7%
NCT00313586 · Phase 2 · registry result, not featured evidence
hemoglobin 75.5%
fatigue 72.4%
leukocytes 58.2%
NCT00313586 · Phase 2 · registry result, not featured evidence · combination
acute renal failure 25%
anemia 25%
leukopenia 25%
NCT00382590 · Phase 2 · registry result, not featured evidence · combination
weakness 14.7%
confusion 11.8%
somnolence 5.9%
NCT00326170 · Phase 2 · registry result, not featured evidence · combination
fatigue 37.5%
nausea 37.5%
diarrhoea 31.3%
NCT02719574 · Phase 1/2 · registry result, not featured evidence
nausea 66.7%
constipation 61.5%
platelet count decreased 46.2%
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
nausea 38.6%
constipation 26.8%
red blood cell count decreased 26.1%
NCT02719574 · Phase 1/2 · registry result, not featured evidence
fatigue 33.3%
headache 33.3%
nausea 27.8%
NCT02719574 · Phase 1/2 · registry result, not featured evidence
hypokalaemia 60%
nausea 60%
abdominal pain 40%
NCT02719574 · Phase 1/2 · registry result, not featured evidence
nausea 55%
vomiting 50%
red blood cell count decreased 35%
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
nausea 42.9%
platelet count decreased 42.9%
constipation 33.3%
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
constipation 50%
nausea 40%
fatigue 35%
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
oedema peripheral 50%
cough 40%
decreased appetite 30%
NCT02719574 · Phase 1/2 · registry result, not featured evidence
nausea 72.7%
constipation 63.6%
asthenia 36.4%
NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination
190 mg
alanine aminotransferase increased 60%
aspartate aminotransferase increased 40%
diarrhoea 40%
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
alanine aminotransferase increased 28.6%
aspartate aminotransferase increased 28.6%
constipation 28.6%
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
alanine aminotransferase increased 80%
constipation 80%
anaemia 40%
NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination
400 mg + 20 mg/m^2i
neutropenia 56.5%
thrombocytopenia 34.8%
diarrhoea 26.1%
NCT04102020 · Phase 3 · combination
show 9 more results
400 mg + 36 mg/m^2
neutropenia 69.6%
thrombocytopenia 56.5%
anaemia 34.8%
NCT04102020 · Phase 3 · combination
400 mg + 50 mg/m^2
neutropenia 80%
thrombocytopenia 55%
anaemia 35%
NCT04102020 · Phase 3 · combination
400 mg + 200 mg
nausea 50%
diarrhoea 43.3%
neutropenia 33.3%
NCT04102020 · Phase 3 · combination
400 mg + 300 mg
nausea 56.3%
neutropenia 56.3%
vomiting 56.3%
NCT04102020 · Phase 3 · combination
nausea 64.8% (placebo 23.2%)
vomiting 60.2% (placebo 9.9%)
diarrhoea 50.4% (placebo 21.5%)
NCT01757535 · Phase 3 · combination
300 mg Days 1-7 (Cohort 2)
anaemia 75%
abdominal pain 50%
decreased appetite 50%
NCT01835587 · Phase 1/2 · registry result, not featured evidence
200 mg Days 1-14 (Cohort 3)
nausea 63.2%
diarrhoea 57.9%
anaemia 42.1%
NCT01835587 · Phase 1/2 · registry result, not featured evidence
200 mg Days 1-7 (Cohort 1)
abdominal pain 66.7%
decreased appetite 66.7%
diarrhoea 66.7%
NCT01835587 · Phase 1/2 · registry result, not featured evidence
150 mg Days 1-14 (Cohort 3A)
nausea 100%
anaemia 75%
blood creatinine increased 75%
NCT01835587 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 1/2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gTreatment context differs: monotherapy versus combination.
  8. hPopulation comparability has not been reviewed for 40 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Azacitidine

Event-Free Survival 17.7 vs 15.7 Azacitidine months20 mg/m^2 + 75 mg/m^2
time to event · months
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
14.6 vs 12.8 Azacitidine months20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
7.72 vs 11.24 Venetoclax + Azacitidine months20 mg/m^2 + 100/200/400 mg + 75 mg/m^2
NCT04266795 · Phase 2 · registry result, not featured evidence · combination
OS 6mo 0.81% (n=174) vs 0.825% (n=174) Azacitidine @ 26wk20 mg/m^2 + 75 mg/m^2
absolute value · percentage points
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
OS Rate at 12 0.646% (n=137) vs 0.693% (n=141) Azacitidine @ 52wk20 mg/m^2 + 75 mg/m^2
absolute value · percentage points
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
Time to AML Transformation NA vs 35.6 Azacitidine months20 mg/m^2 + 75 mg/m^2
time to event · months
HR MDS/CMML Participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
CR/CRi 30.3% (n=208) vs 34.5% (n=206) Azacitidine20 mg/m^2 + 75 mg/m^2
event count · % of participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 63 Participants as posted
CR or Marrow CR 41.8% (n=208) vs 44.2% (n=206) Azacitidine20 mg/m^2 + 75 mg/m^2
event count · % of participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 Participants as posted
Clinical Benefit 36.5% (n=208) vs 37.4% (n=206) Azacitidine20 mg/m^2 + 75 mg/m^2
event count · % of participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 76 Participants as posted
Overall 41.8% (n=208) vs 44.2% (n=206) Azacitidine20 mg/m^2 + 75 mg/m^2
responder rate · % of participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 Participants as posted
show 2 more results
56.3% (n=208) vs 54.4% (n=206) Azacitidine*20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 117 Participants as posted
45.2% (n=208) vs 45.6% (n=206) Azacitidine*20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted
ORR 30.8% (n=208) vs 35.4% (n=206) Azacitidine20 mg/m^2 + 75 mg/m^2
event count · % of participants
NCT03268954 · Phase 3 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
Duration of Complete Response 17.2 vs 13.1 Azacitidine months20 mg/m^2 + 75 mg/m^2
time to event · months
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 15 vs 8.5 Azacitidine months20 mg/m^2 + 75 mg/m^2
time to event · months
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
17.1 vs 18.3 Azacitidine months20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
18.9 vs 18.3 Azacitidine months20 mg/m^2 + 75 mg/m^2
NCT03268954 · Phase 3 · registry result, not featured evidence · combination
RBC Transfusion Independence 47.5% (n=129) vs 44.3% (n=140) Azacitidine20 mg/m^2 + 75 mg/m^2
responder rate · % of participants
Percentage of Participants With RBCs-transfusion Independence
NCT03268954 · Phase 3 · registry result, not featured evidence · combination

+ 62 further endpoints in the CSV export.

Azacitidine (Onureg)

Time to Relapse 10.2 vs 4.9 placebo months
time to event · months
NCT01757535 · Phase 3 · combination
FACIT-Fatigue -3.7 vs -2.5 placebo score
absolute change · score
NCT01757535 · Phase 3 · combination
EQ-5D Index -0.0416 vs -0.0152 placebo score
absolute change · score
NCT01757535 · Phase 3 · combination
Time to EQ-5D Deterioration NA vs NA placebo months
time to event · months
NCT01757535 · Phase 3 · combination
Relapse 75% (n=4)300 mg Days 1-7
responder rate · % of participants
No placebo or comparator arm
NCT01835587 · Phase 1/2 · registry result, not featured evidence
show 3 more results
33.3% (n=3)200 mg Days 1-7 (Cohort 1)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
15.8% (n=19)200 mg Days 1-14 (Cohort 3)
NCT01835587 · Phase 1/2 · registry result, not featured evidence
0% (n=4)150 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence
Time to Relapse 14.87 months300 mg Days 1-7
time to event · months
No placebo or comparator arm
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 452.5 days as posted
show 3 more results
22.73 months*200 mg Days 1-7
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 691.7 days as posted
17.14 months*200 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 521.7 days as posted
21.71 months*150 mg Days 1-14
NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 660.8 days as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azacitidine's landscape · Azacitidine (Onureg)'s landscape